HomeInsightsStock Comparison

Cipla Ltd vs Mankind Pharma Ltd Stock Comparison

Cipla Ltd vs Mankind Pharma Ltd Stock Comparison

Last Updated on: Jun 04, 2025

Key Highlights

  • The Latest Trading Price of Cipla Ltd is ₹ 1472 as of 03 Jun 15:30.
  • The P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 yearsThe P/E Ratio of Mankind Pharma Ltd changed from 48.1 on March 2024 to 48.1 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 yearsThe Market Cap of Mankind Pharma Ltd changed from ₹ 92029 crore on March 2024 to ₹ 92029 crore on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The revenue of Cipla Ltd for the Mar '25 is ₹ 7019 crore as compare to the Dec '24 revenue of ₹ 7294 crore. This represent the decline of -3.78% The revenue of Mankind Pharma Ltd for the Mar '25 is ₹ 3333 crore as compare to the Dec '24 revenue of ₹ 3285 crore. This represent the growth of 1.43%.
  • The ebitda of Cipla Ltd for the Mar '25 is ₹ 1827 crore as compare to the Dec '24 ebitda of ₹ 2210 crore. This represent the decline of -17.35% The ebitda of Mankind Pharma Ltd for the Mar '25 is ₹ 932.5 crore as compare to the Dec '24 ebitda of ₹ 903.08 crore. This represent the growth of 3.26%.
  • The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1225 crore over 8 quarters. This represents a CAGR of 10.87% The net profit of Mankind Pharma Ltd changed from ₹ 494.19 crore to ₹ 424.65 crore over 8 quarters. This represents a CAGR of -7.30% .
  • The Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 yearsThe Dividend Payout of Mankind Pharma Ltd changed from 31.56 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Cipla Ltd

  • Cipla Limited is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Mankind Pharma Ltd

  • Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi.
  • Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006. The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products.
  • It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

Cipla Ltd News Hub

News

Jay Precision Pharmaceuticals acquires 26% stake in AMPIN Energy C&I Eighteen

Jay Precision Pharmaceuticals, subsidiary of Cipla, has completed acquisition of 26% stake...

Read more

29 May 2025 18:48

News

Cipla announced incorporation of subsidiary - CiplaRna GmbH' in Germany

Cipla announced that Cipla (EU), UK, a wholly owned subsidiary of the Company, has incorpo...

Read more

29 May 2025 18:50

News

Cipla to convene AGM

Cipla announced that the 89th Annual General Meeting(AGM) of the company will be held on 1...

Read more

14 May 2025 15:08

News

Board of Cipla recommends final dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Board of Cipla recommends special dividend

Cipla announced that the Board of Directors of the Company at its meeting held on 13 May 2...

Read more

13 May 2025 14:34

News

Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%

On the segmental front, the company's India business revenue was Rs 2,622 crore (up 8% YoY...

Read more

13 May 2025 15:17

Mankind Pharma Ltd News Hub

News

Mankind Pharma Ltd slips for fifth straight session

Mankind Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs ...

Read more

23 May 2025 13:35

News

Mankind Pharma slides after Q4 PAT drops 11% YoY to Rs 421 cr

However, revenue from operations increased 27.19% year-on-year (YoY) to Rs 3,079.37 crore ...

Read more

22 May 2025 15:37

News

Board of Mankind Pharma approves incorporation of WoS in Sri Lanka

The Board of Mankind Pharma at its meeting held on 21 May 2025 has approved the incorporat...

Read more

21 May 2025 18:52

News

Mankind Pharma allots 92,512 equity shares under ESOP

Mankind Pharma has allotted 92,512 equity shares under ESOP on 21 May 2025. Consequent to ...

Read more

21 May 2025 14:16

News

Mankind Pharma to discuss results

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 21 May 2025...

Read more

09 May 2025 10:55

News

Mankind Pharma slides after Q3 PAT slips 16% YoY to Rs 380 cr

However, revenue from operations increased 23.9% year on year (YoY) to Rs 3,230 crore in t...

Read more

24 Jan 2025 12:12

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Mankind Pharma Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Mankind Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Cipla Ltd and Mankind Pharma Ltd

Which company has a larger market capitalization, Cipla Ltd or Mankind Pharma Ltd?

Market cap of Cipla Ltd is 118,949 Cr while Market cap of Mankind Pharma Ltd is 97,012 Cr

What are the key factors driving the stock performance of Cipla Ltd and Mankind Pharma Ltd?

The stock performance of Cipla Ltd and Mankind Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Mankind Pharma Ltd?

As of June 4, 2025, the Cipla Ltd stock price is INR ₹1472.8. On the other hand, Mankind Pharma Ltd stock price is INR ₹2350.85.

How do dividend payouts of Cipla Ltd and Mankind Pharma Ltd compare?

To compare the dividend payouts of Cipla Ltd and Mankind Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions